Try our beta test site

Non Invasive Prenatal Testing (NIPT) of Single-gene Disorders

This study is currently recruiting participants. (see Contacts and Locations)
Verified January 2017 by Maastricht University Medical Center
Sponsor:
Collaborator:
Radboud University
Information provided by (Responsible Party):
Maastricht University Medical Center
ClinicalTrials.gov Identifier:
NCT02339402
First received: January 12, 2015
Last updated: January 12, 2017
Last verified: January 2017
  Purpose
Developing a new non-invasive prenatal test for single gene disorders from cell free fetal DNA, retrieved from the mothers blood.

Condition
Hereditary Disease

Study Type: Observational
Study Design: Observational Model: Cohort
Time Perspective: Prospective
Official Title: NON-INVASIVE PRENATAL TESTING (NIPT) OF FETAL SINGLE-GENE DISORDERS IN MATERNAL BLOOD

Resource links provided by NLM:


Further study details as provided by Maastricht University Medical Center:

Primary Outcome Measures:
  • Development of a targeted molecular test (mostly standard PCR or real-time PCR) for non-invasive prenatal testing of single-gene disorders. [ Time Frame: 2014-2016 ]

    Main aims are to

    1. demonstrate the presence or absence of (a) mutant allele(s) in maternal plasma
    2. examine if there is a sufficient concentration of fetal nucleic acids in the maternal plasma to reliably diagnose the monogenic disorder


Biospecimen Retention:   Samples With DNA
Foetal DNA is isolated from the blood of pregnant women and their partners

Estimated Enrollment: 160
Study Start Date: June 2014
Estimated Study Completion Date: May 2018
Estimated Primary Completion Date: January 2018 (Final data collection date for primary outcome measure)
Detailed Description:

Rationale: Conventional prenatal diagnosis (PND) for single-gene disorders requires invasive procedures, either chorionic villus sampling between 11 and 14 weeks gestation or amniocentesis after 15 weeks. Although these approaches to obtain foetal DNA currently provide the golden standard for PND, the invasive procedures carry a risk of miscarriage of 0.5-1%. A reliable non-invasive alternative has long been sought. Circulating cell-free foetal (cff) nucleic acids (DNA and RNA), which are present in maternal blood during pregnancy, can be used for non-invasive prenatal testing (NIPT). NIPT for some chromosomal anomalies (trisomy 21, 13, 18) is now validated. NIPT for other chromosomal anomalies is still under development. NIPT of single-gene disorders is technically very challenging, due to the predominance of maternal DNA sequences, Some small studies have shown that a very limited number of monogenic genetic disorders can currently be diagnosed in maternal blood. In general de novo mutations in the foetus and paternally transmitted disorders are less difficult to diagnose than maternally transmitted disorders.

In this study, the investigators aim to develop non-invasive targeted molecular analysis using cell free fetal (cff) DNA and cff RNA for single-gene disorders, in pregnant women referred to the departments of Clinical Genetics of Maastricht University Medical Centre (MUMC+) and Radboud University Medical Centre (RUMC) for conventional PND. The investigators will contribute to literature by confirming earlier published results, and by adding other single-gene disorders or mutations to the list of disorders for which the possibility of the use of cff DNA will be examined.

Objective: Developing targeted non-invasive prenatal analysis for single-gene disorders using cff DNA and RNA in maternal plasma.

Study design: This study is a proof of concept study in which we aim to demonstrate that molecular analysis can indicate the presence or absence of (a) mutant allele(s) in maternal plasma.

Study population: Pregnant women (≥18y) referred to the Department of Clinical Genetics of MUMC+ or RadboudUMC for conventional PND, for one of the following reasons:

  • The fetus is at high risk of having inherited a dominant or recessive disorder of his/her affected parent(s).
  • The fetus at risk of having a de novo disorder on the basis of ultrasonography findings.

Main study endpoints: Does targeted molecular analysis of cff DNA and RNA indicate

  1. the presence or absence of (a) mutant allele(s) in maternal plasma
  2. the presence of a sufficient concentration of foetal nucleic acids in the maternal plasma to reliably diagnose the monogenic disorder Nature and extent of the burden and risks associated with participation and benefit: minimal burden: one moment of blood sampling for the pregnant woman and her partner. In most cases the blood sampling will be combined with regular blood sampling. Benefit: no benefit for this pregnancy as in the study phase the result of the invasive prenatal test is leading.
  Eligibility

Ages Eligible for Study:   18 Years to 50 Years   (Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   Yes
Sampling Method:   Probability Sample
Study Population

Pregnant women and their partner (≥18y) that undergo an invasive procedure for prenatal genetic diagnosis in the MUMC+ of RUMC for one of the following indications:

  • fetus at high risk of having inherited a dominant or recessive disorder of his/her affected parent(s) or
  • fetus at risk of having a de novo disorder on the basis of ultrasonography findings.
Criteria

Inclusion Criteria:

  • the pregnant woman is scheduled for or has recently undergone invasive prenatal testing (regular care) because of one of the following reasons:

    • the fetus is at high risk of a having inherited a single-gene disorder from his/her affected parent(s).
    • the fetus is at risk of having a de dominant novo disorder on the basis of ultrasonography findings.
  • the pregnant woman is 18 years or older
  • the pregnant woman has sufficient understanding of Dutch language and is able to give informed consent

Exclusion Criteria:

  • if in the opinion of the treating physician psychological distress is so severe that asking for participation is not safe
  • the pregnant woman is treated for a malignancy
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its ClinicalTrials.gov identifier: NCT02339402

Contacts
Contact: Christine EM de Die, MD PhD 0031433877859 ext 0031433877859 c.dedie@mumc.nl
Contact: Nienke Muntjewerff, MD 0031433877859 ext 0031433877859 nienke.muntjewerff@mumc.nl

Locations
Netherlands
Radboud UMC Recruiting
Nijmegen, Gelderland, Netherlands, 6500HB
Contact: Ilse Feenstra, MD PhD    0031243653678    ilse.feenstra@radboudumc.nl   
Maastricht UMC Recruiting
Maastricht, Netherlands, 6202AZ
Contact: Christine EM de Die, MD PhD    0031433877859 ext 0031433877859    c.dedie@mumc.nl   
Sponsors and Collaborators
Maastricht University Medical Center
Radboud University
Investigators
Principal Investigator: Christine de Die, MD PhD Maastricht UMC
  More Information

Responsible Party: Maastricht University Medical Center
ClinicalTrials.gov Identifier: NCT02339402     History of Changes
Other Study ID Numbers: NL48304/METC azM/UM 14-02-012
Study First Received: January 12, 2015
Last Updated: January 12, 2017

Keywords provided by Maastricht University Medical Center:
Cystic fibrosis, Myotonic dystrophy, Noonan, Huntingtons

Additional relevant MeSH terms:
Genetic Diseases, Inborn

ClinicalTrials.gov processed this record on March 28, 2017